L-arginine analogs--inactive markers or active agents in atherogenesis?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and observational literature without systematic methodology.
PubMed 18855643 · doi:10.2174/187152508785909429
What was done
The authors reviewed literature examining the biological activities and clinical associations of the dimethylated L-arginine analogs asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in endothelial dysfunction, atherogenesis, and cardiovascular disease across clinical cohorts and in vitro models.
What was found
The abstract reports qualitative narrative findings without specific numerical data. ADMA levels were reported to correlate with endothelial dysfunction, atherosclerotic risk factors, and the severity of carotid, coronary, and peripheral atherosclerosis, while predicting adverse outcomes in end-stage renal disease and coronary artery disease. In vitro, proinflammatory cytokines and oxidized LDL increased endothelial ADMA release. ADMA accelerated endothelial replicative senescence via telomerase inhibition and impaired endothelial progenitor cell mobilization. SDMA was described as actively inhibiting nitric oxide synthesis by competing with endothelial L-arginine uptake.
Why it matters
This review highlights methylated arginine derivatives as active pathogenetic drivers of vascular damage and senescence rather than inert biomarkers.
Limits
As a narrative review, it lacks systematic search methodology, meta-analytic pooling, and risk-of-bias evaluation. The abstract provides no quantitative effect sizes, confidence intervals, sample sizes, or cohort details.
Cited by
- supports Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) directly and indirectly inhibit nitric oxide synthase.